npj Parkinsons Disease

Article	Citations
Novel co-culture model of T cells and midbrain organoids for investigating neurodegeneration in Parkinson’s disease	154
SVHRSP protects against rotenone-induced neurodegeneration in mice by inhibiting TLR4/NF-κB-mediated neuroinflammation via gut microbiota	103
Author Correction: A framework for translational therapy development in deep brain stimulation	101
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease	94
Subthalamic nucleus deep brain stimulation alleviates oxidative stress via mitophagy in Parkinson’s disease	85
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders	83
Author Correction: MRgFUS subthalamotomy in Parkinson’s disease: an approach aimed at minimizing Lesion Volume	82
Longitudinal corpus callosum microstructural decline in early-stage Parkinson’s disease in association with akinetic-rigid symptom severity	81
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	81
Fiber-specific micro- and macroscopic white matter alterations in progressive supranuclear palsy and corticobasal syndrome	78
Population fraction of Parkinson’s disease attributable to preventable risk factors	77
Reorganization of intrinsic functional connectivity in early-stage Parkinson’s disease patients with probable REM sleep behavior disorder	75
Author Correction: Neurocognitive correlates of semantic memory navigation in Parkinson’s disease	73
Risk factors associated with age at onset of Parkinson’s disease in the UK Biobank	71
Grey matter networks in women and men with dementia with Lewy bodies	67
Transcriptome analysis in LRRK2 and idiopathic Parkinson’s disease at different glucose levels	66
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease	63
Empirical evidence for biometal dysregulation in Parkinson’s disease from a systematic review and Bradford Hill analysis	62
Predictors of clinically significant quality of life impairment in Parkinson’s disease	62
Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia	61
Brainstem neuromelanin and iron MRI reveals a precise signature for idiopathic and LRRK2 Parkinson’s disease	60
Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor	54
Prospective controlled study on the effects of deep brain stimulation on driving in Parkinson’s disease	54
Nigral glucose metabolism as a diagnostic marker of neurodegenerative parkinsonian syndromes	53
Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism	51

Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?	51
Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures	49
Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein	48
Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies	48
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease	48
Ethnicity- and sex-specific genome wide association study on Parkinson’s disease	47
Discovering genetic mechanisms underlying the co-occurrence of Parkinson’s disease and non-motor traits	46
Expanding causal genes for Parkinson’s disease via multi-omics analysis	45
Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease	45
A multi-site study on sex differences in cortical thickness in non-demented Parkinson’s disease	44
Transcriptomic imputation of genetic risk variants uncovers novel whole-blood biomarkers of Parkinson’s disease	44
Occipital hypoperfusion and motor reserve in Parkinson’s disease: an early-phase 18F-FP-CIT PET study	44
Assessing the clinical utility of inertial sensors for home monitoring in Parkinson’s disease: a comprehensive review	43
rTMS improves dysphagia by inhibiting NLRP3 inflammasome activation and caspase-1 dependent pyroptosis in PD mice	43
Comprehensive real time remote monitoring for Parkinson’s disease using Quantitative DigitoGraphy	43
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI	42
Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human alpha synuclein	42
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances	41
Author Correction: Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	41
The macular inner plexiform layer thickness as an early diagnostic indicator for Parkinson’s disease	39
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease	39
Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test	39
Case-control study of hypertension and Parkinson’s disease	38
Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America	38
Gait impairment-related axonal degeneration in Parkinson’s disease by neurite orientation dispersion and density imaging	38
A systematic review of brain morphometry related to deep brain stimulation outcome in Parkinson’s disease	36
Symptoms assessment and decision to treat patients with advanced Parkinson’s disease based on wearables data	36
In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease	36
Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination	36
Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson	36
Synaptic loss and its association with symptom severity in Parkinson’s disease	35
Author Correction: Eight-hours conventional versus adaptive deep brain stimulation of the subthalamic nucleus in Parkinson’s disease	35
Neurocognitive correlates of semantic memory navigation in Parkinson’s disease	35
Aberrant neurophysiological signaling associated with speech impairments in Parkinson’s disease	35
Glycolysis-enhancing α1-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease	35
Genomic, transcriptomic, and metabolomic profiles of hiPSC-derived dopamine neurons from clinically discordant brothers with identical PRKN deletions	34
Distinguishing features of Parkinson’s disease fallers based on wireless insole plantar pressure monitoring	34
Different effect of hypo- and hypermetabolism on cognition in dementia with Lewy bodies: are they coupled or independent?	34
Elevated α-synuclein levels inhibit mitophagic flux	33
Using former carers’ expertise in peer support for carers of people with Parkinson’s Disease	33
Tools for communicating risk for Parkinson’s disease	32
Intracellular α-synuclein assemblies are sufficient to alter nanoscale diffusion in the striatal extracellular space	32
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease	32
Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy	32
Cholecystectomy and subsequent risk of Parkinson’s disease: a nationwide retrospective cohort study	31
Prospective study of bipolar disorder and neurodegenerative diseases	31
Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson’s disease	30
Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease	30
Radiological markers of CSF α-synuclein aggregation in Parkinson’s disease patients	30
Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study	30

Transcranial direct current stimulation for Parkinson’s disease: systematic review and meta-analysis of motor and cognitive effects	29
Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease	29
Neuroprotective actions of a fatty acid nitroalkene in Parkinson’s disease	29
Reference SVA insertion polymorphisms are associated with Parkinson’s Disease progression and differential gene expression	29
Direct and indirect regulation of β-glucocerebrosidase by the transcription factors USF2 and ONECUT2	29
A nationwide cohort study on diabetes severity and risk of Parkinson disease	28
A PheWAS approach to identify associations of GBA1 variants with comprehensive phenotypes beyond neurological diseases	28
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease	28
Neuroprotective role for RORA in Parkinson’s disease revealed by analysis of post-mortem brain and a dopaminergic cell line	28
A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population	28
Average power and burst analysis revealed complementary information on drug-related changes of motor performance in Parkinson’s disease	27
Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease	27
Differences in brain aging between sexes in Parkinson’s disease	27
A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest	27
Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease	27
Phosphorylation of AQP4 by LRRK2 R1441G impairs glymphatic clearance of IFNγ and aggravates dopaminergic neurodegeneration	26
Identification of motor progression in Parkinson’s disease using wearable sensors and machine learning	26
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	25
PARKIN is not required to sustain OXPHOS function in adult mammalian tissues	25
Specific gut microbiota alterations in essential tremor and its difference from Parkinson’s disease	25
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease	25
A systematic review and meta-analysis of inflammatory biomarkers in Parkinson’s disease	25
Cognition as a mediator for gait and balance impairments in GBA-related Parkinson’s disease	25
A systematic review and meta-analysis on effects of aerobic exercise in people with Parkinson’s disease	24
Speech acoustic indices for differential diagnosis between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy	24
Genome-wide determinants of mortality and motor progression in Parkinson’s disease	24
Distribution of phosphorylated alpha-synuclein in non-diseased brain implicates olfactory bulb mitral cells in synucleinopathy pathogenesis	24
Ultrastructural localization of Porphyromonas gingivalis gingipains in the substantia nigra of Parkinson’s disease brains	24
MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity	23
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	23
Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson’s disease	23
Uncovering the neurophysiology of mood, motivation and behavioral symptoms in Parkinson’s disease through intracranial recordings	23
Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease	23
Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity	22
Axial impairment and falls in Parkinson’s disease: 15 years of subthalamic deep brain stimulation	22
Modulation of subthalamic beta oscillations by movement, dopamine, and deep brain stimulation in Parkinson’s disease	22
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study	22
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease	22
Epigenome-wide association study of peripheral immune cell populations in Parkinson’s disease	22
Treadmill training in Parkinson’s disease is underpinned by the interregional connectivity in cortical-subcortical network	22
Coupling between beta band and high frequency oscillations as a clinically useful biomarker for DBS	22
A review on pathology, mechanism, and therapy for cerebellum and tremor in Parkinson’s disease	22
Silencing Parkinson’s risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability	22
Matters Arising ‘Lewy body disease or diseases with Lewy bodies?’	21
Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils	21
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions	21
Deep nasal sinus cavity microbiota dysbiosis in Parkinson’s disease	20
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease	20
Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease	20
Multi-modality machine learning predicting Parkinson’s disease	19
Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting	19
Establishing a robust triangulation framework to explore the relationship between hearing loss and Parkinson’s disease	19
Relative sparing of dopaminergic terminals in the caudate nucleus is a feature of rest tremor in Parkinson’s disease	19
Enhanced glycolysis-derived lactate promotes microglial activation in Parkinson’s disease via histone lactylation	19
Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism	19
Grip strength, genetic predisposition, and Incident Parkinson’s disease: a prospective cohort study in the UK Biobank	19
A comparative blind study between skin biopsy and seed amplification assay to disclose pathological α-synuclein in RBD	19
Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei	19
Disruption of locus coeruleus-related functional networks in Parkinson’s disease	19
Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis	18
Early constipation predicts faster dementia onset in Parkinson’s disease	18
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease	18
DBS-evoked cortical responses index optimal contact orientations and motor outcomes in Parkinson’s disease	18
Author Correction: Nitrosative stress in Parkinson’s disease	18
Druggable transcriptomic pathways revealed in Parkinson’s patient-derived midbrain neurons	18
Synaptic mechanisms underlying onset and progression of memory deficits caused by hippocampal and midbrain synucleinopathy	18
Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2)	18
A single centre prospective study of three device-assisted therapies for Parkinson’s disease	18
Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers	18
The experience of Anxiety for people with Parkinson’s disease	18
Balance response to levodopa predicts balance improvement after bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease	18
Cytokine and chemokine map of peripheral specific immune cell subsets in Parkinson’s disease	18
Baseline cerebral structural morphology predict freezing of gait in early drug-naïve Parkinson’s disease	18
Depressive symptoms in Parkinson’s disease are insufficiently but more often treated than in other chronic conditions	18
Comparative efficacy of surgical approaches to disease modification in Parkinson disease	17
Microbial biomarker discovery in Parkinson’s disease through a network-based approach	17
CRBN modulates synuclein fibrillation via degradation of DNAJB1 in mouse model of Parkinson disease	17
Parkinson’s disease is associated with clonal hematopoiesis with TET2 mutation	17
Author Correction: Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease	17
Lipid level alteration in human and cellular models of alpha synuclein mutations	17

White matter and nigral alterations in multiple system atrophy-parkinsonian type	17
Deficiency of Perry syndrome-associated p150Glued in midbrain dopaminergic neurons leads to progressive neurodegeneration and endoplasmic reticulum abnormalities	17
Altered parabrachial nucleus nociceptive processing may underlie central pain in Parkinson’s disease	17
Serum lipid profile among sporadic and familial forms of Parkinson’s disease	17
Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutation	17
Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers	17
Parkinson’s disease gene, Synaptojanin1, dysregulates the surface maintenance of the dopamine transporter	17
CSF markers of neurodegeneration Alzheimer’s and Lewy body pathology in isolated REM sleep behavior disorder	16
AccessPD as a next generation registry to accelerate Parkinson’s disease research	16
MRI subtypes in Parkinson’s disease across diverse populations and clustering approaches	16
Genetic variation and pesticide exposure influence blood DNA methylation signatures in females with early-stage Parkinson’s disease	16
Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain	16
Delayed orthostatic hypotension in Parkinson’s disease	15
A versatile computational algorithm for time-series data analysis and machine-learning models	15
Redefining the hypotheses driving Parkinson’s diseases research	15
Cathepsin L-containing exosomes from α-synuclein-activated microglia induce neurotoxicity through the P2X7 receptor	15
Advanced brain aging in Parkinson’s disease with cognitive impairment	15
Comprehensive subtyping of Parkinson’s disease patients with similarity fusion: a case study with BioFIND data	15
A transcriptome-wide association study identifies susceptibility genes for Parkinson’s disease	15
First delirium episode in Parkinson’s disease and parkinsonism: incidence, predictors, and outcomes	15
Author Correction: Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson’s study	15
A severe neurodegenerative disease with Lewy bodies and a mutation in the glucocerebrosidase gene	15
The effect of levodopa on bilateral coordination and gait asymmetry in Parkinson’s disease using inertial sensor	15
Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson’s disease	15
Detecting Parkinson’s disease and its cognitive phenotypes via automated semantic analyses of action stories	15
Awake versus asleep deep brain stimulation targeting the caudal zona incerta for essential tremor	15
Self-reported periodontitis and C-reactive protein in Parkinson’s disease: a cross-sectional study of two American cohorts	15
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease	15
Mapping of catecholaminergic denervation, neurodegeneration, and inflammation in 6-OHDA-treated Parkinson’s disease mice	14
Corneal confocal microscopy differentiates patients with Parkinson’s disease with and without autonomic involvement	14
Effects of deep brain stimulation frequency on eye movements and cognitive control	14
Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson’s disease	14
Common and distinct roles of amygdala subregional functional connectivity in non-motor symptoms of Parkinson’s disease	14
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies	14
Male sex accelerates cognitive decline in GBA1 Parkinson’s disease	14
Temporal and spatial variability of dynamic microstate brain network in early Parkinson’s disease	14
α-Synuclein induced cholesterol lowering increases tonic and reduces depolarization-evoked synaptic vesicle recycling and glutamate release	14
Social isolation and the risk of Parkinson disease in the UK biobank study	14
Change in the incidence of Parkinson’s disease in a large UK primary care database	14
The elephant in the room: critical reflections on mortality rates among individuals with Parkinson’s disease	14
Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease	14
Z/Ce@hemin enzymes with enhanced peroxidase activity for monitoring and screening the oxidative stress models of Parkinson’s disease	14
Clinical classification systems and long-term outcome in mid- and late-stage Parkinson’s disease	14
Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration	14
Magnetic susceptibility changes in the brainstem reflect REM sleep without atonia severity in isolated REM sleep behavior disorder	14
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	14
Linking acetylated α-Tubulin redistribution to α-Synuclein pathology in brain of Parkinson’s disease patients	14
Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review	14
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	14